Craft
  • Home
  •  / Bluebird Bio
Bluebird Bio

Bluebird Bio

Patents and Patent Applications

1.22 K

FY, 2020

Revenue

$3.7 M

FY, 2021

Market Capitalization

$415.7 M

2022-09-19

Bluebird Bio Summary

Company summary

Overview
Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer. The company works on programs in severe genetic diseases that include betibeglogene autotemcel (beti-cel; formerly LentiGlobin gene therapy for β-thalassemia); LentiGlobin gene therapy for sickle cell disease, or SCD; and elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy for cerebral adrenoleukodystrophy, or CALD). Its programs in oncology are focused on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.
Type
Public
Founded
1992
HQ
Cambridge, MA, US | view all locations
Website
https://www.bluebirdbio.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Melissa Bonner

    Melissa Bonner, Senior Vice President, Research

  • Jason F. Cole

    Jason F. Cole, Chief Strategy and Financial Officer

  • Elizabeth Pingpank

    Elizabeth Pingpank, Director, Investor Relations

  • Anne-Virginie Eggimann

    Anne-Virginie Eggimann, Chief Regulatory Officer

Operating MetricsView all

Patents and Patent Applications

1.2K
4.1%

FY, 2020

LocationsView all

10 locations detected

  • Cambridge, MA HQ

    United States

    60 Binney St

  • Durham, NC

    United States

    1733 TW Alexander Dr

  • Seattle, WA

    United States

    188 E Blaine St #300

  • Paris, IDF

    France

    75 Boulevard Haussmann

  • München, BY

    Germany

    Josephspitalstraße 15

  • Athens

    Greece

    166A, Kifissias Avenue & 2 Sofokleous Str. GR-151 26 Maroussi

and 4 others

Bluebird Bio Financials

Summary financials

Revenue (Q2, 2022)
$1.3M
Cash (Q2, 2022)
$81.5M
Enterprise value
$627.2M

Footer menu